In a step forward for bispecific antibodies, study results presented at ASH suggest a Tecvayli-based combination could have ...

While early, study results presented at ASH show Tern’s drug could surpass Novartis’ Scemblix and “raise the bar in efficacy” ...

The deal, which includes another $200 million in potential payouts, hands the California biotech a candidate in late-stage ...

Dyne is readying a competitor to Sarepta’s Exondys 51. Elsewhere, a pair of obesity drugs showed promise and Kymera’s protein ...

The data and AI algorithms within companion apps can help HCPs provide a diagnosis quicker, allowing them to compare their ...